People · Operator
Named in public records as an officer, director or promoter · active 2012–2016 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Achelios Therapeutics, Inc. | — | Pharmaceuticals | Seed | $5.4M | $13.3M | 2012 |
| Exodos Life Sciences Limited Partnership | — | Pharmaceuticals | Pre-Seed | $2.7M | $32.6M | 2014 |
| Verinetics, Inc. | — | Other Technology | Pre-Seed | $2.0M | $453K | 2015 |
Ron J. Vered at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ron J. Vered on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Crist Frangakis | 2 | 2 |
| Crist J. Frangakis | 2 | 2 |
| William J. Dickie | 2 | 2 |
| Jerry J. Rosenblatt | 2 | 2 |
| Petra Weishaupt-Smith | 1 | 2 |
| Thomas Mercolino | 1 | 1 |
| Ron Vered | 1 | 1 |
| Ed Erickson | 1 | 1 |
| Thomas J. Mercolino | 1 | 1 |
| Petra J. Weishaupt-Smith | 1 | 1 |
| Jessica S. Beaver | 1 | 1 |
| William J. Bauer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.